GLPG ostatnio wybrał BridgeneBio.
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration and licensing agreement with BridGene Biosciences, Inc. (“Bridgene”), a biotechnology company that uses proprietary chemoproteomics technology to discover novel small molecule drug candidates.
Liczba konkurentów MOC rośnie. MOC na peronie, póki co...
A w Spółce są osoby związane z GLPG i Gilead.